ELAB vs. CARM, GELS, LPCN, APRE, LPTX, MIRA, OKUR, COCP, NNVC, and GLYC
Should you be buying Elevai Labs stock or one of its competitors? The main competitors of Elevai Labs include Carisma Therapeutics (CARM), Gelteq (GELS), Lipocine (LPCN), Aprea Therapeutics (APRE), Leap Therapeutics (LPTX), MIRA Pharmaceuticals (MIRA), OnKure Therapeutics (OKUR), Cocrystal Pharma (COCP), NanoViricides (NNVC), and GlycoMimetics (GLYC). These companies are all part of the "pharmaceutical products" industry.
Elevai Labs vs.
Carisma Therapeutics (NASDAQ:CARM) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation, community ranking and institutional ownership.
Elevai Labs has a net margin of -223.41% compared to Carisma Therapeutics' net margin of -314.78%. Elevai Labs' return on equity of -124.93% beat Carisma Therapeutics' return on equity.
Carisma Therapeutics received 17 more outperform votes than Elevai Labs when rated by MarketBeat users.
Carisma Therapeutics currently has a consensus price target of $4.94, indicating a potential upside of 966.95%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Carisma Therapeutics is more favorable than Elevai Labs.
Elevai Labs has lower revenue, but higher earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks.
In the previous week, Carisma Therapeutics had 1 more articles in the media than Elevai Labs. MarketBeat recorded 1 mentions for Carisma Therapeutics and 0 mentions for Elevai Labs. Carisma Therapeutics' average media sentiment score of 0.00 equaled Elevai Labs'average media sentiment score.
Carisma Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Elevai Labs has a beta of -3.28, meaning that its share price is 428% less volatile than the S&P 500.
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 22.2% of Elevai Labs shares are owned by institutional investors. 12.6% of Carisma Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Elevai Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Carisma Therapeutics beats Elevai Labs on 11 of the 17 factors compared between the two stocks.
Get Elevai Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elevai Labs Competitors List
Related Companies and Tools
This page (NASDAQ:ELAB) was last updated on 2/22/2025 by MarketBeat.com Staff
